• Viking Therapeutics (VKTX) is trading about 6% up at $32.20 in pre-market, continuing a sharp rebound.
  • The rally follows fresh takeover chatter after CNBC highlighted the biotech as a potential acquisition target.
  • Investor enthusiasm is also fueled by a scheduled meeting with B. Riley and renewed confidence in the company's weight-loss pipeline, with analysts backing its key obesity drug candidate VK2735.